Lab21, IntegraGen Co-developing CDx for Colorectal Cancer Therapy | GenomeWeb

NEW YORK (GenomeWeb News) – Lab21 today announced an agreement with IntegraGen to develop a microRNA-based assay to identify colorectal cancer patients who may best respond to EGFR-inhibitor therapy.

Lab21 will develop an assay based on its SPARQ PCR technology to detect the expression levels of a miRNA biomarker called hsa-mir-31-3p. IntegraGen and its academic partners discovered and patented the biomarker, which has shown an ability to predict EGFR-inhibitor response in KRAS wild-type patients with metastatic colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.